Understand your PSA result and the UK age-related thresholds, then explore Heracles monitoring with doctor review and clear follow-up.
PSA often rises with age as the prostate becomes larger. The table below explains UK referral thresholds and what your result may mean. They are not normal ranges or diagnostic cut-offs: a low result cannot rule out cancer, and a raised result does not diagnose it.
With Heracles, your PSA result comes with doctor review, an explanation and a record of changes over time. Our clinical team includes consultant urologists and andrologists, with Peter Grice as Clinical Lead. Explore Heracles PSA monitoring.
Your result is assessed alongside age, symptoms, ethnicity, family history, medicines, infection, prostate size, examination and previous tests. The applicable UK referral pathway matters too.
There is no single PSA number that is normal for everyone.
PSA is a continuous measure: the risk of prostate cancer does not suddenly begin at one particular number, and some prostate cancers produce relatively little PSA.
It is more useful to ask whether a PSA result is expected for the individual and whether it needs repeat testing or further assessment.
PSA is reported in ng/mL or µg/L. The numerical value is the same in either unit. For example, 3.5 ng/mL equals 3.5 µg/L.
For men with possible symptoms of prostate cancer, Cancer Research UK summarises age-related PSA thresholds used to support urgent suspected-cancer referral in England, Wales and Northern Ireland.
These thresholds guide referral for men with possible symptoms. They are not screening cut-offs or personal treatment targets.
| Age | PSA level that may support urgent referral |
|---|---|
| Under 40 | Use clinical judgement |
| 40–49 | Above 2.5 ng/mL |
| 50–59 | Above 3.5 ng/mL |
| 60–69 | Above 4.5 ng/mL |
| 70–79 | Above 6.5 ng/mL |
| 80 and over | Use clinical judgement |
Scotland uses a different national framework for men with possible symptoms. Cancer Research UK summarises thresholds of 3 ng/mL or more for men under 70, 5 ng/mL or more for men aged 70–79, and 20 ng/mL or more for men aged 80 and over.
Scottish guidance also advises PSA testing from age 80 when clinical features suggest metastatic prostate cancer or when the man requests testing after shared decision-making. Clinical judgement and the responsible local pathway remain essential.
Benign prostate enlargement becomes more common with age, so PSA tends to rise even when cancer is not present.
Higher age-related thresholds can reduce unnecessary referrals and biopsies. The trade-off is that no threshold can identify every clinically significant cancer.
This is why symptoms, examination findings and personal risk factors can justify further investigation even when PSA is below an age-related referral threshold.
A PSA below an age-related referral threshold may still warrant further assessment if there is a suspicious prostate examination, persistent concerning symptoms, a strong family history, Black ethnicity, a pathogenic BRCA2 variant, a previous lower baseline or another clinical concern. An extremely low PSA and significant urinary symptoms can also be concerning for rare variants of prostate cancer.
NICE recommends referral when the prostate feels suspicious for cancer on examination, regardless of the PSA level.
PSA varies naturally between tests. The European Association of Urology notes that, among men with PSA below 10 ng/mL, roughly one third can differ by more than 1 ng/mL at a second measurement.
Infection, ejaculation, vigorous exercise and recent prostate procedures can also cause a temporary rise.
When PSA is moderately raised and the prostate examination is not suspicious, a clinician may repeat the test under standardised conditions before deciding on the next step.
Repeat testing is not appropriate when the PSA level, symptoms or examination findings require urgent action.
Several PSA results can show whether the level is broadly stable, fluctuating or rising.
A sustained rise can be useful information; small changes may reflect biological or laboratory variation. A stable PSA does not completely exclude cancer.
PSA velocity describes the rate at which PSA changes over time. It is not a stand-alone test for prostate cancer and should not be used to make decisions without considering the wider clinical picture.
PSA density takes prostate size into account when interpreting the PSA level.
A larger benign prostate can naturally produce more PSA, so comparing PSA with prostate volume can sometimes help refine the assessment of cancer risk.
PSA density is usually calculated using prostate volume measured on MRI or ultrasound. It can be useful in selected clinical pathways but is not interpreted on its own.
Finasteride and dutasteride, which are used to treat benign prostate enlargement and, in some cases, hair loss, can reduce PSA by around half. The effect varies between individuals.
Tell the clinician the medicine you take, the dose and how long you have been taking it so that the result can be interpreted correctly.
Do not stop treatment for a PSA test unless the prescriber advises you to do so.
Higher PSA values generally increase the likelihood that a significant prostate problem is present, but there is still no PSA value that diagnoses cancer by itself.
Infection, acute urinary retention and marked benign prostate enlargement can all produce substantial PSA rises.
A clearly high result needs timely clinical assessment rather than online interpretation or a delayed, self-directed repeat test.
No.
Cancer Research UK estimates that around 7–15% of men with a PSA result considered normal may still have prostate cancer.
Some uncommon or aggressive prostate cancers can produce relatively little PSA. This is one reason PSA should never be interpreted on its own.
A clinician should assess persistent symptoms or a suspicious prostate examination even if the PSA level is not raised.
Heracles combines scheduled at-home tests, laboratory analysis and doctor review in one monitoring plan. Each result is explained and added to your record, with guidance on the next step. Our clinical leadership includes Professor Suks Minhas, Professor Tet Yap and Peter Grice.
Start your PSA assessment or explore Heracles PSA monitoring. If a result needs further investigation, the team can support a GP handover or discuss appropriate private options. Additional investigations are separate from the monitoring plan.
